No Data
No Data
Top Executives Cash Out Millions in Protagonist Therapeutics Stock!
Insider Sale: Chief Medical Officer of $PTGX Sells 30,514 Shares
J.P. Morgan Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $70 to $80
Protagonist Therapeutics Analyst Ratings
Unlock the Full List